Study of ficerafusp alfa with pembrolizumab for head and neck cancer
Treatments studied
Part of Bones, joints & muscles, Cancer, Ear, nose & throat, Genetic & congenital, Lungs & breathing clinical trials.
This study tests a new drug called ficerafusp alfa combined with pembrolizumab (an immunotherapy) in people with head and neck cancer that has returned or spread. The drug targets a protein that may help the immune system fight the cancer. The study is comparing two different schedules of giving the drug to see which is better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have head and neck cancer that has returned or spread.
- The cancer must be in certain areas (mouth, throat, voice box, or tonsils) and must not be caused by the HPV virus if in the throat.
- You must not have received prior treatment for the returned or spread cancer.
- If you had chemotherapy or radiation as part of your first treatment, it must have finished more than 6 months ago.
- Your tumor must show a certain level of PD-L1 protein.
- You must have at least one tumor that can be measured by imaging.
- You must be able to perform daily activities with minimal assistance (ECOG 0 or 1).
- You must have adequate organ function.
- You must not have other serious medical conditions like active autoimmune disease, bleeding, or infections (HIV, hepatitis B or C).
- You must not have received certain drugs (EGFR inhibitors, immune checkpoint inhibitors) within the last 6 months or any prior anti-TGF-beta therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two medications, ficerafusp alfa and nivolumab, for people with head and neck cancer that has progressed after platinum-based treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) plus targeted radiation before surgery for head and neck cancer. The goal is to see if this approach can shrink the tumor or help the surgery be more effective.
Hear when a new Metastatic Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.